Immunology Investor Event

Rilzabrutinib is being evaluated in multiple Phase 2 clinical trials across a range of indications sanofi Target Population Clinical Trial Design AD Inadequately controlled with topicals; adults 18 or older; moderate-severe Placebo-controlled, 2 dose levels N=120 Primary efficacy evaluated at week 16 Asthma Add-on to ICS and second controller; adults 18-70 yrs, moderate-severe Placebo-controlled, 2 dose levels N=192 Primary efficacy at week 12 CSU moderate-severe disease; inadequate response to oral anti-H1 Placebo-controlled, 3 dose levels N=152 Primary efficacy evaluated at week 12 IgG4 Adult patients with IgG4-RD 2 arms, open label N=25 Primary efficacy evaluated at week 12 Primary Endpoint Change in EASI Score Loss of Asthma Control Positioning Best-in-class in oral BTKi class 36 Immunology Investor Event First-in-class ISS7/UAS7 Best-in-class Phase 2 readouts in 2023 and 2024 IgG4-RD RI First-in-class

View entire presentation